NovoCure's Profit After Tax fell 2191.69% to -$37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$177.6 million, marking a year-over-year decrease of 1860.41%. This contributed to the annual value of -$168.6 million for FY2024, which is 1855.46% up from last year.
Per NovoCure's latest filing, its Profit After Tax stood at -$37.3 million for Q3 2025, which was down 2191.69% from -$40.1 million recorded in Q2 2025.
NovoCure's 5-year Profit After Tax high stood at -$4.1 million for Q1 2021, and its period low was -$65.9 million during Q4 2024.
Moreover, its 5-year median value for Profit After Tax was -$34.3 million (2025), whereas its average is -$33.6 million.
As far as peak fluctuations go, NovoCure's Profit After Tax tumbled by 104183.34% in 2023, and later surged by 4187.36% in 2024.
Quarter analysis of 5 years shows NovoCure's Profit After Tax stood at -$26.5 million in 2021, then tumbled by 40.99% to -$37.3 million in 2022, then decreased by 26.21% to -$47.1 million in 2023, then plummeted by 40.02% to -$65.9 million in 2024, then soared by 43.46% to -$37.3 million in 2025.
Its Profit After Tax stands at -$37.3 million for Q3 2025, versus -$40.1 million for Q2 2025 and -$34.3 million for Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value